Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS

COVID-19 Clinical Trial

— NIRS-COV  

Official title:

Effects of Cardiovascular and Pulmonary Optimisation on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04392089
• Other study ID #: H-20027818
• Status: Recruiting
• Start date: May 1, 2020
• Est. completion date: May 1, 2021

Study information

• Verified date: May 2020
• Source: Hvidovre University Hospital
• Contact: Ana-Marija Hristovska, MD, Ph.d.-student
• Phone: +4538625532
• Email: ana-marija.hristovska.02[@]regionh.dk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the present study is to examine whether cerebral oxygenation could be a more useful parameter than peripheral oxygen saturation to guide clinical titration of permissive hypoxemia in COVID-19 ARDS patients

Description:

Mechanical ventilation is the cornerstone of supportive management for most ARDS patients to prevent life-threatening hypoxemia. Arterial oxygenation can be improved via ventilator by increasing fractional inspired oxygen (FiO2) and/or increasing mean airway pressure. When treating mechanically ventilated ARDS patients, the benefit of improved arterial oxygenation must be balanced against the potential risk of ventilator-induced lung injury (VILI), oxygen toxicity occurring with high FiO2 and development of right heart failure.

Arterial oxygen saturation target of 88-95 % and partial oxygen pressure (PaO2) target of 7.3-10.6 are advocated in the management of patients with ARDS. Surprisingly little randomized evidence exists to support these values and current recommendations are thus arbitrary and largely based on normal physiologic values.

Given the lack of evidence of strategies in oxygenating critically ill patients to an oxygen saturation and partial oxygen pressure that is generally accepted to be 'normal,' permissive hypoxemia may offer an alternative that has the potential to improve patient outcomes by avoiding unnecessary harm. Permissive hypoxemia is a concept in which a lower level of arterial oxygenation than usual is accepted in order to avoid the potentially detrimental effects of high fractional inspired oxygen and invasive mechanical ventilation with high pressures, while maintaining adequate oxygen delivery by optimizing cardiac output.

Pulse oximetry is a simple, non-invasive and universally used method to monitor peripheral oxygen saturation of hemoglobin in a variety of clinical settings. Pulse oximetry depends on pulsatile blood flow and only measures the oxyhemoglobin in arterial blood as it leaves the heart. However, this measure does not provide information regarding organ or tissue oxygenation, which reflects the important local balance between oxygen supply and demand.

Near-infrared spectroscopy (NIRS) allows for continuous measurement of regional tissue oxygenation which reflects perfusion status and enables clinicians to directly monitor fluctuations in real time. NIRS reflects the balance of oxygen that is delivered minus what is extracted at tissue level and is an indicator of the tissue oxygen uptake.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: May 1, 2021
• Est. primary completion date: May 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Verified COVID-19 infection (throat swab or tracheal aspirate positive for SARS-CoV-2)

• Severe ARDS according to Berlin definition

• Ventilator settings: Controlled IPPV, FiO2 > 0.70, PEEP > 10

• Norepinephrine infusion

• SVV < 10% measured by LiDCO

• RASS - 5

Exclusion Criteria:

• Any of the following contraindications to lung recruitment: pneumothorax, patients on ventilator > 1 week

• Patients with dark pigmented skin

Related Conditions & MeSH terms

• COVID-19
• Respiratory Failure
• Respiratory Insufficiency

Intervention

Device:
• Masimo, LidCO
Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO

Locations

Country	Name	City	State
Denmark	Hvidovre Hospital	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Hvidovre University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization: Step 0 = Baseline, Step 1 = Derecruitment, Step 2 = Recruitment, Step 3 = Norepinephrine challenge, Step 4 = FiO2 increase, Step 5 = FiO2 decrease, Step 6 = Baseline 2	1 hour
Secondary	Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in heart rate (HR) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in stroke volume (SV) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in cardiac output (CO) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in pH during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in PaO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in PaCO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in PvO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in PvCO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in lacatate during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour
Secondary	Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization	Cardiovascular and pulmonary optimization as described above	1 hour